Please provide your email address to receive an email when new articles are posted on . INDIAN WELLS, Calif. — Intravitreal injection of microplasmin may be effective as a nonsurgical treatment for ...

An enzyme injected into the vitreous cavity in patients with vitreomacular adhesion may release focal points of contact, thus obviating the need for surgical intervention for relief of vitreomacular ...

Alcon announces EU approval of Jetrea®, first and only eye drug to treat sight-threatening vitreomacular traction and macular hole One-time intravitreal injection of Jetrea has shown efficacy in the ...

July 27, 2012 — An advisory committee to the US Food and Drug Administration (FDA) voted July 26 to recommend ocriplasmin (Jetrea, ThromboGenics, Inc) 125 μg intravitreal injection for the treatment ...

- Microplasmin Shows Clear Promise in Back of the Eye Disease, With Treated Patients Achieving Macular Hole Closure and Traction Release Without Need for Vitrectomy ThromboGenics NV (Euronext Brussels ...

Stalmans et al. (Aug. 16 issue) 1 report that intravitreal injection of ocriplasmin was superior to injection of placebo in altering the vitreoretinal interface of affected eyes. It was associated ...

LEUVEN, Belgium, December 4, 2007 -- - Microplasmin Shows Clear Promise in Back of the Eye Disease, With Treated Patients Achieving Macular Hole Closure and Traction Release Without Need for ...

In two ancillary studies of two multi-center international clinical trials, the injectable drug ocriplasmin appears to improve vision among patients suffering from symptomatic vitreomacular adhesion ...

To study the efficacy of a single intravitreal injection of expansile gas as a valuable alternative to current treatment options (conservative, pharmacological, and surgical) in patients with ...

August 15, 2012 — Significantly more patients who received ocriplasmin experienced resolution of vitreomacular adhesions and closure of macular holes than patients who received placebo, according to ...